Celgene Corp insider trades: Acceleron Pharma (XLRN) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Celgene Corp reports to the SEC
and 3 more companies
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 9, 2020 | XLRN | ↓ Sell | 2,241 | $102.28 | $229K | Direct | Jul 13, 2020 (4d) |
| Jul 1, 2020 | XLRN | ↑ Buy | 108,108 | $92.50 | $10.0M | Direct | Jul 6, 2020 (5d) |
| Nov 12, 2019 | AGIO | ↑ Buy | 403,225 | $31.00 | $12.5M | Direct | Nov 14, 2019 (2d) |
| Jan 18, 2019 | XLRN | ↑ Buy | 706,206 | $43.00 | $30.4M | Direct | Jan 22, 2019 (4d) |
| Nov 21, 2018 | CRSP | ↓ Sell | 1,112,446 | $18.98 | $21.1M | See explanation of responses | Dec 7, 2017 (0d) |
| Jan 23, 2018 | AGIO | ↑ Buy | 851,154 | $67.00 | $57.0M | Direct | Jan 23, 2018 (0d) |
| Sep 25, 2017 | XLRN | ↑ Buy | 745,592 | $37.00 | $27.6M | Direct | Sep 25, 2017 (0d) |
| Apr 24, 2017 | AGIO | ↑ Buy | 624,575 | $49.50 | $30.9M | Indirect | Apr 24, 2017 (0d) |
| Feb 27, 2017 | ALQA | ↑ Buy | 4,000,000 | $0.50 | $2.0M | Direct | Mar 1, 2017 (2d) |
| Feb 1, 2017 | JNCE | ↑ Buy | 625,000 | $16.00 | $10.0M | Direct | Feb 1, 2017 (0d) |
| Oct 24, 2016 | CRSP | ↑ Buy | 800,150 | $14.00 | $11.2M | Direct | Oct 26, 2016 (2d) |
| Jan 11, 2016 | XLRN | ↑ Buy | 800,000 | $40.00 | $32.0M | Direct | Jan 11, 2016 (0d) |
| May 4, 2015 | ALQA | ↑ Buy | 659,340 | $4.55 | $3.0M | Direct | May 4, 2015 (0d) |
| Jul 8, 2014 | GBIM | ↑ Buy | 200,000 | $10.00 | $2.0M | Indirect | Jul 8, 2014 (0d) |
| May 5, 2014 | XLRN | ↑ Buy | 1,100,000 | $42.86 | $47.1M | Direct | May 6, 2014 (1d) |
| Apr 29, 2014 | AGIO | ↑ Buy | 294,800 | $44.00 | $13.0M | Indirect | Apr 30, 2014 (1d) |
| Apr 14, 2014 | ALQA | ↑ Buy | 714,286 | $7.00 | $5.0M | Direct | Apr 15, 2014 (1d) |
| Feb 10, 2014 | EPZM | ↑ Buy | 340,000 | $29.25 | $9.9M | Direct | Feb 11, 2014 (1d) |
| Jan 28, 2014 | XLRN | ↑ Buy | 300,000 | $50.00 | $15.0M | Direct | Jan 29, 2014 (1d) |
| Sep 24, 2013 | XLRN | ↑ Buy | 666,667 | $15.00 | $10.0M | Direct | Sep 26, 2013 (2d) |
| Jul 29, 2013 | AGIO | ↑ Buy | 708,333 | $18.00 | $12.7M | Indirect | Jul 30, 2013 (1d) |
| Jun 5, 2013 | EPZM | ↑ Buy | 66,666 | $15.00 | $1000K | Direct | Jun 6, 2013 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Celgene Corp's insider trades
Celgene Corp is a 10% owner of Acceleron Pharma (XLRN). Since Jun 5, 2013, it has reported 20 open-market purchases worth $342.4M and 2 sales worth $21.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (7 filings), other transactions (2 filings), option exercises (1 filing), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every XLRN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.